The United States Bankruptcy Court for the District of Delaware approved this week the sale of the business assets of Benson Hill, St. Louis, to Confluence Genetics, LLC. This sale, which closed May ...
Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing. Fourth quarter GAAP gross margin of 71.7%, ...
Hosted on MSN
Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops
Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year was close to analysts’ estimates with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results